PMID-sentid	Pub_year	Sent_text	compound_name	comp_offset	prot_official_name	organism	prot_offset
33922533-8	2021	Here, we tested the effect of the ADAM17 inhibitor GW280264X in combination with cisplatin on ovarian cancer cells in 2D and 3D.	GW280264X	51-60	ADAM metallopeptidase domain 17	Homo sapiens	34-40
12714508-5	2003	The hydroxamate GW280264X, capable of blocking TACE as well as ADAM10, proved to be an effective inhibitor of the constitutive and the PMA-inducible CX3CL1 cleavage in CX3CL1-expressing ECV-304 cells (CX3CL1-ECV-304), whereas GI254023X, preferentially blocking ADAM10 but not TACE, reduced the constitutive cleavage only.	GW280264X	16-25	ADAM metallopeptidase domain 17	Homo sapiens	47-51
12714508-5	2003	The hydroxamate GW280264X, capable of blocking TACE as well as ADAM10, proved to be an effective inhibitor of the constitutive and the PMA-inducible CX3CL1 cleavage in CX3CL1-expressing ECV-304 cells (CX3CL1-ECV-304), whereas GI254023X, preferentially blocking ADAM10 but not TACE, reduced the constitutive cleavage only.	GW280264X	16-25	ADAM metallopeptidase domain 10	Homo sapiens	63-69
12714508-5	2003	The hydroxamate GW280264X, capable of blocking TACE as well as ADAM10, proved to be an effective inhibitor of the constitutive and the PMA-inducible CX3CL1 cleavage in CX3CL1-expressing ECV-304 cells (CX3CL1-ECV-304), whereas GI254023X, preferentially blocking ADAM10 but not TACE, reduced the constitutive cleavage only.	GW280264X	16-25	C-X3-C motif chemokine ligand 1	Homo sapiens	149-155
12714508-5	2003	The hydroxamate GW280264X, capable of blocking TACE as well as ADAM10, proved to be an effective inhibitor of the constitutive and the PMA-inducible CX3CL1 cleavage in CX3CL1-expressing ECV-304 cells (CX3CL1-ECV-304), whereas GI254023X, preferentially blocking ADAM10 but not TACE, reduced the constitutive cleavage only.	GW280264X	16-25	C-X3-C motif chemokine ligand 1	Homo sapiens	168-174
12714508-5	2003	The hydroxamate GW280264X, capable of blocking TACE as well as ADAM10, proved to be an effective inhibitor of the constitutive and the PMA-inducible CX3CL1 cleavage in CX3CL1-expressing ECV-304 cells (CX3CL1-ECV-304), whereas GI254023X, preferentially blocking ADAM10 but not TACE, reduced the constitutive cleavage only.	GW280264X	16-25	C-X3-C motif chemokine ligand 1	Homo sapiens	168-174
12714508-5	2003	The hydroxamate GW280264X, capable of blocking TACE as well as ADAM10, proved to be an effective inhibitor of the constitutive and the PMA-inducible CX3CL1 cleavage in CX3CL1-expressing ECV-304 cells (CX3CL1-ECV-304), whereas GI254023X, preferentially blocking ADAM10 but not TACE, reduced the constitutive cleavage only.	GW280264X	16-25	ADAM metallopeptidase domain 10	Homo sapiens	261-267
12714508-5	2003	The hydroxamate GW280264X, capable of blocking TACE as well as ADAM10, proved to be an effective inhibitor of the constitutive and the PMA-inducible CX3CL1 cleavage in CX3CL1-expressing ECV-304 cells (CX3CL1-ECV-304), whereas GI254023X, preferentially blocking ADAM10 but not TACE, reduced the constitutive cleavage only.	GW280264X	16-25	ADAM metallopeptidase domain 17	Homo sapiens	276-280
30826330-8	2019	Thus, recent progress has identified the "sheddase" activity of ADAMs as a viable target and the development of GW280264X is an experimental ADAM17 inhibitor.	GW280264X	112-121	ADAM metallopeptidase domain 17	Homo sapiens	141-147
19432809-6	2009	This release was inhibited by the metalloproteinase inhibitor batimastat; however, ADAM10/ADAM17 inhibitor GW280264X only partially affected shedding activity.	GW280264X	107-116	ADAM metallopeptidase domain 10	Homo sapiens	83-89
19432809-6	2009	This release was inhibited by the metalloproteinase inhibitor batimastat; however, ADAM10/ADAM17 inhibitor GW280264X only partially affected shedding activity.	GW280264X	107-116	ADAM metallopeptidase domain 17	Homo sapiens	90-96
15215246-5	2004	The hydroxamate GW280264X, which is capable of blocking TACE and the closely related disintegrin-like metalloproteinase 10 (ADAM10), effectively inhibited both spontaneous and PMA-inducible cleavage of IL-15Ralpha, whereas GI254023X, which preferentially blocks ADAM10, was ineffective.	GW280264X	16-25	a disintegrin and metallopeptidase domain 17	Mus musculus	56-60
15215246-5	2004	The hydroxamate GW280264X, which is capable of blocking TACE and the closely related disintegrin-like metalloproteinase 10 (ADAM10), effectively inhibited both spontaneous and PMA-inducible cleavage of IL-15Ralpha, whereas GI254023X, which preferentially blocks ADAM10, was ineffective.	GW280264X	16-25	a disintegrin and metallopeptidase domain 10	Mus musculus	124-130
15215246-5	2004	The hydroxamate GW280264X, which is capable of blocking TACE and the closely related disintegrin-like metalloproteinase 10 (ADAM10), effectively inhibited both spontaneous and PMA-inducible cleavage of IL-15Ralpha, whereas GI254023X, which preferentially blocks ADAM10, was ineffective.	GW280264X	16-25	interleukin 15 receptor, alpha chain	Mus musculus	202-213
15215246-5	2004	The hydroxamate GW280264X, which is capable of blocking TACE and the closely related disintegrin-like metalloproteinase 10 (ADAM10), effectively inhibited both spontaneous and PMA-inducible cleavage of IL-15Ralpha, whereas GI254023X, which preferentially blocks ADAM10, was ineffective.	GW280264X	16-25	a disintegrin and metallopeptidase domain 10	Mus musculus	262-268
33045304-6	2021	Increased MICA shedding was prevented by the ADAM inhibitor GW280264X, rendering BCSC as sensitive to gammadeltaTc cytotoxicity as NSC.	GW280264X	60-69	MHC class I polypeptide-related sequence A	Homo sapiens	10-14
29662625-11	2018	Inhibition of ADAM17 with either GW280264X or the anti-ADAM17 antibody D1 (A12) as well as silencing of ADAM17 by siRNA selectively reduced AREG release.	GW280264X	33-42	ADAM metallopeptidase domain 17	Homo sapiens	14-20
28264989-5	2017	With respect to the inhibitor profile, we found that ADAM9 was inhibited by the hydroxamate-based metalloprotease inhibitors marimastat, TAPI-2, BB94, GM6001 and GW280264X, and by 10 nM of the tissue inhibitor of metalloproteinases (TIMP)-3, but not by up to 20 nM of TIMP-1 or -2.	GW280264X	162-171	ADAM metallopeptidase domain 9	Homo sapiens	53-58
22367719-3	2012	In vitro, endotoxin-mediated induction of endothelial permeability and IL-8-induced transmigration of neutrophils through human microvascular endothelial cells required ADAM17 as shown by inhibition with GW280264X or shRNA-mediated knockdown.	GW280264X	204-213	C-X-C motif chemokine ligand 8	Homo sapiens	71-75
22367719-3	2012	In vitro, endotoxin-mediated induction of endothelial permeability and IL-8-induced transmigration of neutrophils through human microvascular endothelial cells required ADAM17 as shown by inhibition with GW280264X or shRNA-mediated knockdown.	GW280264X	204-213	ADAM metallopeptidase domain 17	Homo sapiens	169-175
22367719-6	2012	Induced vascular permeability, oedema formation, release of TNF-alpha and IL-6 and pulmonary leukocyte recruitment were all markedly reduced by GW280264X or endothelial adam17-knockout.	GW280264X	144-153	tumor necrosis factor	Homo sapiens	60-69
22367719-6	2012	Induced vascular permeability, oedema formation, release of TNF-alpha and IL-6 and pulmonary leukocyte recruitment were all markedly reduced by GW280264X or endothelial adam17-knockout.	GW280264X	144-153	interleukin 6	Homo sapiens	74-78
21111811-6	2011	GW280264X that targets both ADAM10 and ADAM17 blocked IL-6-induced proliferation and ERK1/2 phosphorylation with same potency as GM6001.	GW280264X	0-9	ADAM metallopeptidase domain 10	Homo sapiens	28-34
21111811-6	2011	GW280264X that targets both ADAM10 and ADAM17 blocked IL-6-induced proliferation and ERK1/2 phosphorylation with same potency as GM6001.	GW280264X	0-9	ADAM metallopeptidase domain 17	Homo sapiens	39-45
21111811-6	2011	GW280264X that targets both ADAM10 and ADAM17 blocked IL-6-induced proliferation and ERK1/2 phosphorylation with same potency as GM6001.	GW280264X	0-9	interleukin 6	Homo sapiens	54-58
21111811-6	2011	GW280264X that targets both ADAM10 and ADAM17 blocked IL-6-induced proliferation and ERK1/2 phosphorylation with same potency as GM6001.	GW280264X	0-9	mitogen-activated protein kinase 3	Homo sapiens	85-91
19455579-7	2009	Inhibition of ADAM10 activity by the hydroxamate-based inhibitors GI254023X and GW280264X resulted in a significant decrease in the mean axonal length.	GW280264X	80-89	ADAM metallopeptidase domain 10	Rattus norvegicus	14-20
18305178-7	2008	Addition of the MP inhibitors GM6001, TNF-alpha-converting enzyme inhibitor 2, or GW280264X strongly reduced selenium-induced L-selectin shedding, indicating a MP-dependent mechanism.	GW280264X	82-91	selectin L	Homo sapiens	126-136
16227584-3	2005	Spontaneous and inducible Axl cleavage was inhibited by the broad-spectrum metalloproteinase inhibitor GM6001 and by hydroxamate GW280264X, which is capable of blocking ADAM10 and ADAM17.	GW280264X	129-138	AXL receptor tyrosine kinase	Mus musculus	26-29
16227584-3	2005	Spontaneous and inducible Axl cleavage was inhibited by the broad-spectrum metalloproteinase inhibitor GM6001 and by hydroxamate GW280264X, which is capable of blocking ADAM10 and ADAM17.	GW280264X	129-138	a disintegrin and metallopeptidase domain 10	Mus musculus	169-175
16227584-3	2005	Spontaneous and inducible Axl cleavage was inhibited by the broad-spectrum metalloproteinase inhibitor GM6001 and by hydroxamate GW280264X, which is capable of blocking ADAM10 and ADAM17.	GW280264X	129-138	a disintegrin and metallopeptidase domain 17	Mus musculus	180-186
15777180-7	2005	By contrast, the compound did not affect the PMA-induced shedding, which was only blocked by GW280264X, a potent inhibitor of ADAM17.	GW280264X	93-102	ADAM metallopeptidase domain 17	Homo sapiens	126-132